Kangas, Brian D.
Iturra-Mena, Ann M.
Robble, Mykel A.
Luc, Oanh T.
Potter, David
Nickels, Stefanie
Bergman, Jack
Carlezon, William A. Jr.
Pizzagalli, Diego A.
Funding for this research was provided by:
National Institute of Mental Health (UH2-MH109334)
Article History
Received: 2 December 2020
Accepted: 18 May 2021
First Online: 3 June 2021
Competing interests
: Over the past 3 years, Dr. Pizzagalli has received consulting fees from Albright Stonebridge Group, BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathway, Concert Pharmaceuticals, Engrail Therapeutics, Neurocrine Biosciences, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals as well as one honorarium from Alkermes. In addition, he has received stock options from BlackThorn Therapeutics, and research support from National Institute of Mental Health, Dana Foundation, Brain and Behavior Research Foundation, and Millennium Pharmaceuticals. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. Over the past three years. Dr. Carlezon has received consulting fees from Psy Therapeutics. None of the other authors have any conflict of interest or disclosures with regard to the work presented in this manuscript.